Literature DB >> 12478115

An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma.

Ricardo F Sánchez-Ortiz1, William C Huang, Rosemarie Mick, Keith N Van Arsdalen, Alan J Wein, S Bruce Malkowicz.   

Abstract

PURPOSE: The standard of care for muscle invasive transitional cell carcinoma of the bladder is radical cystectomy. Definitive therapy may often be delayed for various reasons. We assessed whether pathological stage and survival correlated with the length of time between diagnosis of muscle invasion and cystectomy.
MATERIALS AND METHODS: The records of 290 consecutive patients who underwent radical cystectomy between February 1987 and July 2000 were reviewed. Of 265 (91.4%) cystectomies performed for transitional cell carcinoma data were available for 247 (85.2%) and 189 (65.2%) patients were identified who underwent surgery for muscle invasive disease (T2 or greater). The interval between diagnosis of muscle invasion and cystectomy was calculated for each patient. Patients were divided into groups based on time to surgery as group 1-less than 4 weeks, 2-4 to 6 weeks, 3-7 to 9 weeks, 4-10 to 12 weeks, 5-13 to 16 weeks, and 6-greater than 16 weeks. Exploratory univariate and multivariate analyses were performed to test the association of time lag with clinical features and postoperative survival.
RESULTS: Mean patient age was 66 years (range 37 to 84) and overall 3-year Kaplan-Meier estimated survival was 59.1% +/- 4% (median followup 36 months). For all patients mean interval from diagnosis to cystectomy was 7.9 weeks (range 1 to 40). Extravesical disease (P3a or greater) or positive nodes were identified in 84% (16 of 19) of patients when the delay was longer than 12 weeks, compared with 48.2% (82 of 170) in those with a time lag of 12 weeks or less (p < 0.01). Similarly 3-year estimated survival was lower (34.9% +/- 13.5%) for patients with a surgery delay longer than 12 weeks compared to those with a shorter interval 62.1% +/- 4.5% (hazards ratio 2.51, 95% CI 1.30-4.83, p = 0.006). When adjusted for nodal status, and clinical and pathological stages the interval was still statistically significant (adjusted hazards ratio 1.93, 95% CI 0.99-3.76, p = 0.05).
CONCLUSIONS: In patients undergoing radical cystectomy a delay in surgery of greater than 12 weeks was associated with advanced pathological stage and decreased survival. Although this relationship persisted after adjusting for nodal status, and clinical and pathological stages, the presence of lymph node metastasis remained the strongest predictor of patient outcome.

Entities:  

Mesh:

Year:  2003        PMID: 12478115     DOI: 10.1097/01.ju.0000039620.76907.0d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  52 in total

1.  Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy.

Authors:  M Gierth; R Mayr; A Aziz; S Krieger; B Wullich; A Pycha; M Lodde; U Salvadori; J Bründl; H M Fritsche; F Hofstädter; M T Pawlik; W Otto; M May; M Burger; S Denzinger
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-02       Impact factor: 4.553

Review 2.  [Standards and perspectives in diagnosis and therapy of bladder carcinoma].

Authors:  C Stief; D Zaak; M Stöckle; U Studer; R Knuechel; C Rödel; R Sauer; H Rubben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 3.  Neoadjuvant chemotherapy for bladder cancer.

Authors:  Peter C Black; Gordon A Brown; H Barton Grossman; Colin P Dinney
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

4.  Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer.

Authors:  Alan So
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

Review 5.  Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.

Authors:  Yuanbin Ru; Garrett M Dancik; Dan Theodorescu
Journal:  Curr Opin Urol       Date:  2011-09       Impact factor: 2.309

6.  Perioperative chemotherapy for muscle-invasive bladder cancer.

Authors:  Peter Black; Alan So
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

7.  Clinical trials: nationally representative data in urology.

Authors:  Jay B Shah; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

Review 8.  Bladder cancer in the elderly.

Authors:  Shahrokh F Shariat; Matthew Milowsky; Michael J Droller
Journal:  Urol Oncol       Date:  2009 Nov-Dec       Impact factor: 3.498

9.  Prognostic impact of comorbidity in patients with bladder cancer.

Authors:  Ifeanyichukwu I Megwalu; Anna Vlahiotis; Mohamed Radwan; Jay F Piccirillo; Adam S Kibel
Journal:  Eur Urol       Date:  2007-11-05       Impact factor: 20.096

10.  Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis.

Authors:  John L Gore; Julie Lai; Claude M Setodji; Mark S Litwin; Christopher S Saigal
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.